TLC Provides Corporate Update at Investor Conference – Dec 18, 2020
The Pharma Data
DECEMBER 17, 2020
The trial remains on-track to complete enrollment of all 500 patients in the United States and Australia before the end of 2020, despite the worsening of the COVID-19 pandemic. In its Phase II clinical trial, TLC599 significantly reduced pain at and through every scheduled visit through six months.
40 
Let's personalize your content